Abstract
PLA2 is an important signaling enzyme that generates multiple downstream effectors, such as arachidonic acid and PAF, which are key mediators of inflammation as well as other pathophysiological conditions. Inhibition of PLA2 is potentially an effective therapy for several inflammatory diseases. In this review, we discuss the various classes of synthetic inhibitors of Group IVA and Group VIA phospholipase A2.
Keywords: Analgesic, anti-inflammatory agents, inflammation, inhibitors, 2-oxoamide, pain, phospholipase A2, trifluoromethyl ketone
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Synthetic Inhibitors of Group IVA and Group VIA Phospholipase A2
Volume: 5 Issue: 2
Author(s): Victoria Magrioti and George Kokotos
Affiliation:
Keywords: Analgesic, anti-inflammatory agents, inflammation, inhibitors, 2-oxoamide, pain, phospholipase A2, trifluoromethyl ketone
Abstract: PLA2 is an important signaling enzyme that generates multiple downstream effectors, such as arachidonic acid and PAF, which are key mediators of inflammation as well as other pathophysiological conditions. Inhibition of PLA2 is potentially an effective therapy for several inflammatory diseases. In this review, we discuss the various classes of synthetic inhibitors of Group IVA and Group VIA phospholipase A2.
Export Options
About this article
Cite this article as:
Magrioti Victoria and Kokotos George, Synthetic Inhibitors of Group IVA and Group VIA Phospholipase A2, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2006; 5 (2) . https://dx.doi.org/10.2174/187152306776872451
DOI https://dx.doi.org/10.2174/187152306776872451 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based Therapeutics
Current Pharmaceutical Design The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Design of Protective and Therapeutic DNA Vaccines for the Treatment of Allergic Diseases
Current Drug Targets - Inflammation & Allergy Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Current Drug Discovery Technologies Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) The Potential Role of the Endocannabinoid System in the Control of Multiple Scleorsis
Current Medicinal Chemistry - Central Nervous System Agents GABAergic Agonists Modulate the Glutamate Release from Frontal Cortex Synaptosomes of Rats with Experimental Autoimmune Encephalomyelitis
Inflammation & Allergy - Drug Targets (Discontinued) Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets